Results 11 to 20 of about 94,936 (269)

Docetaxel-related interstitial pneumonitis

open access: yesTherapeutics and Clinical Risk Management, 2015
Chung-Jen Wang, Hou-Tai Chang, Cheng-Yu Chang Division of Chest Medicine, Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan Abstract: Docetaxel (Taxotere®) is an agent that is indicated for the treatment of ...
Wang CJ, Chang HT, Chang CY
doaj   +1 more source

Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy : results from the BIG 02-98 phase III trial [PDF]

open access: yes, 2012
Introduction: Pre-clinical data suggest p53-dependent anthracycline-induced apoptosis and p53-independent taxane activity. However, dedicated clinical research has not defined a predictive role for TP53 gene mutations. The aim of the current study was to
Viale, Giuseppe   +16 more
core   +5 more sources

Docetaxel suppressed cell proliferation through Smad3/HIF-1α-mediated glycolysis in prostate cancer cells

open access: yesCell Communication and Signaling, 2022
Background Tumor glycolysis is a critical event for tumor progression. Docetaxel is widely used as a first-line drug for chemotherapy and shown to have a survival advantage.
Junming Peng   +6 more
doaj   +1 more source

Study of the Effect of Linoleic Acid on the Expression Level of MicroRNA-106b and MicroRNA-20a and their Related Target MHC Class I Chain-related Protein A in Docetaxel-treated Gastric Cancer Cells [PDF]

open access: yesMiddle East Journal of Cancer, 2021
Background: MicroRNAs are involved in response to therapeutic agents and have the ability to regulate the expression level of the targets associated with cancer growth and progression.
Najibeh Shekari   +6 more
doaj   +1 more source

CD44v8-10 mRNA contained in serum exosomes as a diagnostic marker for docetaxel resistance in prostate cancer patients

open access: yesHeliyon, 2020
Background: Docetaxel is first-line chemotherapy for castration-resistant prostate cancer (CRPC), but most patients acquire docetaxel resistance. CD44 has been shown to be involved in drug resistance of cancers including prostate cancer.
Taku Kato   +5 more
doaj   +1 more source

The key cellular senescence related molecule RRM2 regulates prostate cancer progression and resistance to docetaxel treatment

open access: yesCell & Bioscience, 2023
Background Prostate cancer is a leading cause of cancer-related deaths among men worldwide. Docetaxel chemotherapy has proven effective in improving overall survival in patients with castration-resistant prostate cancer (CRPC), but drug resistance ...
Bisheng Cheng   +11 more
doaj   +1 more source

High efficacy and low toxicity of weekly docetaxel given as first-line treatment for metastatic breast cancer [PDF]

open access: yes, 2005
Background: Docetaxel is one of the most effective antitumor agents currently available for the treatment of metastatic breast cancer (MBC). This phase II multicenter study prospectively analyzed the efficacy and toxicity of docetaxel given on a weekly ...
Abenhardt, Wolfgang   +29 more
core   +1 more source

Prospective Multicenter Randomized Phase III Study of Weekly versus Standard Docetaxel (D2) for First-Line Treatment of Metastatic Breast Cancer [PDF]

open access: yes, 2010
Purpose: Previous phase II studies have indicated a greatly reduced hematotoxicity of docetaxel-based regimens administered on weekly schedules. The present trial was initiated to randomly compare the toxicity and efficacy of weekly docetaxel versus its ...
Abenhardt, Wolfgang   +23 more
core   +1 more source

Transcription factor network analysis based on single cell RNA-seq identifies that Trichostatin-a reverses docetaxel resistance in prostate Cancer

open access: yesBMC Cancer, 2021
Background Overcoming drug resistance is critical for increasing the survival rate of prostate cancer (PCa). Docetaxel is the first cytotoxic chemotherapeutical approved for treatment of PCa.
Patricia M. Schnepp   +7 more
doaj   +1 more source

Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02) : an open-label, phase 3 randomised controlled trial [PDF]

open access: yes, 2013
Background: Second-line chemotherapy for patients with oesophagogastric adenocarcinoma refractory to platinum and fluoropyrimidines has not shown benefits in health-related quality of life (HRQoL). We assessed whether the addition of docetaxel to active
Cliona C Kirwan (10530920)   +845 more
core   +2 more sources

Home - About - Disclaimer - Privacy